Comparison · NCT01027910-19bf97dc
Optional GCSF vs Mandatory GCSF: Rate of Progression-free Survival at 6 Months in Participants Who Received PCI-24781/Doxorubicin Combination Administration.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Optional GCSF vs Mandatory GCSF: Rate of Progression-free Survival at 6 Months in Participants Who Received PCI-24781/Doxorubicin Combination Administration. Trial comparisons, record NCT01027910-19bf97dc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01027910-19bf97dc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.0301 | 0.564 | wilson | |
| Risk in group 2 | 0.429 | 0.214 | 0.674 | wilson | |
| Risk difference, group 1 minus group 2 | -0.262 | -0.543 | 0.189 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.389 | 0.0588 | 2.57 | log | |
| Odds ratio, group 1 over group 2 | 0.267 | 0.0243 | 2.92 | log | |
| Number needed to treat, for one fewer participant with the outcome on Optional GCSF than on Mandatory GCSF | 3.82 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Optional GCSF | 1 | 6 | OG000 | |
| Group 2 | Mandatory GCSF | 6 | 14 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Rate of Progression-free Survival at 6 Months in Participants Who Received PCI-24781/Doxorubicin Combination Administration.
- Description
- Time frame
- 2 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- PCI-24781 in Combination With Doxorubicin to Treat Sarcoma
- NCT number
- NCT01027910
- Phases
- PHASE1, PHASE2
- Conditions
- Sarcoma
- Interventions
- PCI-24781, Doxorubicin, GCSF
- Lead sponsor
- Massachusetts General Hospital
- Results first posted
- 2017-02-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01027910?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01027910-19bf97dc